These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25500418)

  • 1. Sociodemographic correlates of fecal immunotesting for colorectal cancer screening.
    Crouse A; Sadrzadeh SM; de Koning L; Naugler C
    Clin Biochem; 2015 Feb; 48(3):105-9. PubMed ID: 25500418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity and Specificity of Community Fecal Immunotesting Screening for Colorectal Carcinoma in a High-Risk Canadian Population.
    Crouse AL; De Koning L; Sadrzadeh SM; Naugler C
    Arch Pathol Lab Med; 2015 Nov; 139(11):1441-5. PubMed ID: 26516941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sociodemographic correlates of urine culture test utilization in Calgary, Alberta.
    Griener TP; Naugler C; Chan WW; Church DL
    BMC Urol; 2018 Jan; 18(1):2. PubMed ID: 29310636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A feces collection paper does not enhance participation in a fecal immunochemical test-based colorectal cancer screening program: randomized clinical trial.
    Denters MJ; Deutekom M; Bossuyt PM; Fockens P; Dekker E
    Eur J Cancer Prev; 2013 Jul; 22(4):299-304. PubMed ID: 23169243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
    Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
    Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stool Testing for Colorectal Cancer Screening.
    Robertson DJ; Imperiale TF
    Gastroenterology; 2015 Oct; 149(5):1286-93. PubMed ID: 26033632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial.
    Hoffman RM; Steel S; Yee EF; Massie L; Schrader RM; Murata GH
    Prev Med; 2010; 50(5-6):297-9. PubMed ID: 20307568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia.
    Lane JM; Chow E; Young GP; Good N; Smith A; Bull J; Sandford J; Morcom J; Bampton PA; Cole SR
    Gastroenterology; 2010 Dec; 139(6):1918-26. PubMed ID: 20723544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program.
    Chiang TH; Chuang SL; Chen SL; Chiu HM; Yen AM; Chiu SY; Fann JC; Chou CK; Lee YC; Wu MS; Chen HH
    Gastroenterology; 2014 Dec; 147(6):1317-26. PubMed ID: 25200099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of sociodemographic factors and prostate-specific antigen (PSA) testing.
    Gorday W; Sadrzadeh H; de Koning L; Naugler C
    Clin Biochem; 2014 Nov; 47(16-17):164-9. PubMed ID: 25130956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
    Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
    J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated screening with fecal immunochemical tests reduced the incidence of colorectal cancers in Saga, Japan.
    Sakata N; Sakata Y; Shimoda R; Sakata H; Iwakiri R; Fujimoto K; Mizuguchi M; Irie H; Shimoda Y; Noshiro H
    Hepatogastroenterology; 2014; 61(133):1224-8. PubMed ID: 25436287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing and Risk Factors for a Positive Fecal Immunochemical Test in Subsequent Screening for Colorectal Neoplasms.
    Chiang TH; Lee YC; Liao WC; Chung JH; Chiu HM; Tu CH; Chen SC; Wu MS
    PLoS One; 2015; 10(9):e0136890. PubMed ID: 26332318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial.
    van Roon AH; Hol L; van Vuuren AJ; Francke J; Ouwendijk M; Heijens A; Nagtzaam N; Reijerink JC; van der Togt AC; van Ballegooijen M; Kuipers EJ; van Leerdam ME
    Am J Gastroenterol; 2012 Jan; 107(1):99-107. PubMed ID: 22108450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends and inequities in colorectal cancer screening participation in Ontario, Canada, 2005-2011.
    Honein-AbouHaidar GN; Baxter NN; Moineddin R; Urbach DR; Rabeneck L; Bierman AS
    Cancer Epidemiol; 2013 Dec; 37(6):946-56. PubMed ID: 23702337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening.
    van Roon AH; Goede SL; van Ballegooijen M; van Vuuren AJ; Looman CW; Biermann K; Reijerink JC; Mannetje H'; van der Togt AC; Habbema JD; van Leerdam ME; Kuipers EJ
    Gut; 2013 Mar; 62(3):409-15. PubMed ID: 22387523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.